KZIA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Kazia Therapeutics Ltd (KZIA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, there is no strong trading sentiment from options data, and no recent positive news or financial data to support a buy decision. While the analyst rating is positive with an increased price target, the lack of significant catalysts and bearish short-term trends suggest holding off on investing for now.
The technical indicators for KZIA are bearish. The MACD is negatively expanding below 0 (-0.052), RSI is neutral at 21.598, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot point of 5.7, with key support at 5.062 and resistance at 6.338.
H.C. Wainwright raised the price target to $18 from $13, citing encouraging Phase 1 study results for paxalisib in treating triple-negative breast cancer.
No significant trading trends from hedge funds or insiders. No recent news or congress trading data. Bearish technical indicators and short-term stock trend projections (-1.06% next day, -2.97% next week, -2.31% next month).
No financial data available for analysis.
H.C. Wainwright maintains a Buy rating and raised the price target to $18 from $13, citing promising clinical trial results.
